AN2 THERAPEUTICS INC (ANTX)
US0373261058 - Common Stock
ChartMill assigns a Buy % Consensus number of 78% to ANTX. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 10.54. This target is 710.77% above the current price.
ANTX was analyzed by 11 analysts. The buy percentage consensus is at 78. So analysts seem to be have mildly positive about ANTX.
In the previous month the buy percentage consensus was at a similar level.
ANTX was analyzed by 11 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-11-19 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-11-18 | TD Cowen | Downgrade | Buy -> Hold |
| 2024-08-09 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2024-07-03 | Leerink Partners | Upgrade | Market Perform -> Outperform |
| 2024-05-16 | Evercore ISI Group | Maintains | In-Line -> In-Line |
| 2024-04-02 | JMP Securities | Upgrade | Market Perform -> Market Outperform |
| 2024-04-01 | Oppenheimer | Reiterate | Perform -> Perform |
| 2024-02-13 | Leerink Partners | Downgrade | Outperform -> Market Perform |
| 2024-02-12 | JMP Securities | Downgrade | Market Outperform -> Market Perform |
| 2024-02-12 | Oppenheimer | Downgrade | Outperform -> Perform |
| 2024-02-12 | Evercore ISI Group | Downgrade | Outperform -> In-Line |
| 2024-01-04 | JMP Securities | Initiate | Market Outperform |
| 2023-03-30 | Oppenheimer | Maintains | Outperform |
| 2022-11-14 | SVB Leerink | Maintains | Outperform |
| 2022-04-19 | Oppenheimer | Initiate | Outperform |
| 2022-04-19 | Cowen & Co. | Initiate | Outperform |
| 2022-04-19 | Evercore ISI Group | Initiate | Outperform |